


A NOVEL BLOOD TEST FOR THE EARLY DETECTION OF ESOPHAGEAL CANCER

PromarkerEso

powered by **Proteomics International**



Correctly identified 94% of patients with the disease
Correctly identified 94% of patients not having EAC

Over 290 patients studied across 3 independent cohorts
Early screening could prevent cancer progression



- Esophageal cancer (EAC) is the 6th leading cause of cancer-related death and the 7th most common cancer, affecting over 600,000 people every year globally¹




- Esophageal adenocarcinoma incidence has increased by 600% over the past 40 years² and is the predominant type of esophageal cancer in Western countries³



- The 5-year EAC survival rate is only 10%-20% with little progress made in reducing its impact⁴ and there remains a crucial need for early intervention to improve outcomes

Current Diagnosis



Diagnosis currently requires a specialist endoscopy-biopsy procedure, which is costly and invasive

Endoscopic screening for BE in individuals >50 years with chronic GERD symptoms is recommended, but 90% of EAC cases remain




Despite effective treatment strategies, current screening/surveillance has not impacted the rising incidence of EAC⁶

The PromarkerEso test combines the concentration of 4 glycoprotein biomarkers with age and BMI using a bi-model logistic regression approach

Clinical Studies and Collaborations

The PromarkerEso test was developed and validated in 292 serum samples from three independent cohorts

- ✓ The Progression of Barrett's Esophagus to Cancer Network (PROBE-NET) Cohort (N=103), Australia
- ✓ OCHSNER cohort (N=24), United States
- ✓ Victorian BioBank (N=166), Australia



PromarkerEso demonstrated an excellent discrimination performance (AUC-ROC: 0.82-0.93)

In the VCB validation cohort, the PromarkerEso test:

- Identified 94% of patients in the high-risk category as having EAC
- Identified 94% of patients in the low-risk category as not having EAC
- Demonstrated very high sensitivity (93%) and specificity (97%)

Test Results and Interpretation



PromarkerEso Risk Categories

PromarkerEso test results are presented using a traffic light approach with **low-**, **moderate-** or **high-** risk of EAC, based on two cut-offs to optimise test performance:

- Low/Moderate-risk cut-off - provides optimal sensitivity to increase true positives.
- Moderate/High-risk cut-off - provides optimal specificity to reduce false positives.

REVOLUTIONISING ESOPHAGEAL CANCER DETECTION

Esophageal Cancer


PromarkerEso

Endometriosis

PromarkerEndo

Diabetic Kidney Disease

PromarkerD



Proteomics International

6 Verdun Street, Perth, WA, 6009

+61 8 9389 1992

www.proteomics.com.au

@proteomicsi

References:

(1) Sung et al. (2020), CA Cancer J Clin, 2021;71:209-49. doi: 10.3322/caac.21660. (2) Then et al (2020), World J Conol, doi: 10.14740/wjon1254. (3) Rustgi et al. (2014), N Engl J Med, doi: 10.1056/NEJMra1314530. (4) Thrift et al (2021), Nat Rev Gastroenterol Hepatol, doi: 10.1038/s41575-021-00419-3 (5) Joseoh et al. (2022), Cleveland Clin J Med, doi: 10.3949/cjcm.89a.21053. (6) Dam et al. (2020), Ann Transl Med, doi: 10.21037/atm-20-4406